血脂康抑制高脂血症患者单核细胞粘附

为探讨调脂药血脂康在治疗高脂血症的同时 ,是否具有抑制粘附分子表达的作用。用血脂康治疗 15例高脂血症 ,治疗 4周前后用流式细胞仪双标法 (CD11b/CD14 )测定其外周血单核细胞和淋巴细胞粘附分子CD11b的表达 ,以及单核细胞与内皮细胞的粘附率。结果发现 ,治疗前后单核细胞表面CD11b的相对荧光强度和平均荧光强度均下降。淋巴细胞表面CD11b的相对荧光强度和平均荧光强度以及表达的百分率也降低。单核细胞与内皮细胞的粘附率从 5 .5 0 %± 2 .30 %降低到 1.75 %± 0 .85 % (P <0 .0 5 )。CD11b单克隆抗体封闭后可以抑制其粘附。此结果提示 ,他汀类药物血脂康在临床治疗过程中可以抑制粘附分子表达 ,发挥其降脂以外的作用。

Inhibiting Effects of Xuezhikang on Monocytes adhesion in the Patients with H ypercholesterolemia

Aim To determine whether Xuezhikang, a HMG CoA reductase inhibito r made in China, affects CD11b expression and adhesiveness of monocytes to endot helial cells in vitro after the treatment of patients with hypercholesterolemia. Methods Fifteen patients with hypercholesterolemia were treated with Xuezhikang (1.2 g/d) for 4 weeks. Isolated human blood monoc ytes were subject to flow cytometric detection of CD11b and adhesion assays to l ive human endothelial cells were made before and after the treatments of Xuezhik ang. Results The average fluorescence intensity and the relative fluorescence intensity of CD11b expressed in monocytes and lymphocy tes from the peripheral venous blood were lowered after the treatment of Xuezhik ang. The expression rate of CD11b in lymphocytes was decreased from 27%±4% to 13%±3% (p<0.05,n=15). The adhesion rate of mo nocytes to endothelial cells was reduced from 5.5%±2.3% to 1.8%±0.8%(p<0.05,n=15). Pretreatment of CD11b mAb in vitro ca n inhibit the adhesion of monoctyes to endothelial cells. Conclus ions Xuezhikang, a kind of HMG CoA reductase inhibitor, can inhi bit the expression of CD11b in monoctyes and the adhesion of monocytes to endoth elial cells with the cholesterol loweing effects. The nonlipid mechanisms may involve in it.